• +1-646-491-9876
    • +91-20-67278686

    Search

    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1-Pipeline Review H2 2017

    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1-Pipeline Review H2 2017

    • Report Code ID: RW0001881473
    • Category Life Sciences
    • No. of Pages 51
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Pipeline Review H2 2017

    Summary

    According to the recently published report 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1-Pipeline Review H2 2017'; Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis.

    The report 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1-Pipeline Review H2 2017' outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase I Preclinical and Discovery stages are 2 4 and 4 respectively. Similarly the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease) Pancreatic Cancer Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Breast Cancer Colorectal Cancer Head And Neck Cancer Hematological Tumor Malignant Mesothelioma Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Myelodysplastic Syndrome Ovarian Cancer Prostate Cancer Refractory Multiple Myeloma Relapsed Multiple Myeloma and Solid Tumor.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
    - The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Overview
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Companies Involved in Therapeutics Development
    AbbVie Inc
    Amgen Inc
    AstraZeneca Plc
    Complix NV
    Les Laboratoires Servier SAS
    Takeda Pharmaceutical Company Ltd
    Warp Drive Bio Inc
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Drug Profiles
    AMG-176-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-5991-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FL-118-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Proteins to Inhibit MCL-1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-63845-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-64315-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MCL-1 for Breast Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MCL-1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MCL-1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MCL1 for Multiple Myeloma-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MCL1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MCL1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    UMI-77-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Dormant Products
    Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Product Development Milestones
    Featured News & Press Releases
    Mar 31 2017 Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
    Oct 20 2016 New compound shows promise in treating multiple human cancers
    Apr 28 2015 Camptothecin Analog FL118 Can Overcome Treatment Resistance Outperform Approved Therapies
    Dec 15 2014 Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
    Dec 31 2013 Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    Dec 31 2013 Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    Apr 02 2013 Roswell Park Scientists Advance Findings about Novel Low-Toxicity Anticancer Agent
    Sep 20 2012 RPCI Scientists Publish Findings About Novel Anticancer Agent
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by AbbVie Inc H2 2017
    Pipeline by Amgen Inc H2 2017
    Pipeline by AstraZeneca Plc H2 2017
    Pipeline by Complix NV H2 2017
    Pipeline by Les Laboratoires Servier SAS H2 2017
    Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
    Pipeline by Warp Drive Bio Inc H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    AbbVie Inc
    Amgen Inc
    AstraZeneca Plc
    Complix NV
    Les Laboratoires Servier SAS
    Takeda Pharmaceutical Company Ltd
    Warp Drive Bio Inc

    Request for Sample

    Report Url http://www.reportsweb.com//induced-myeloid-leukemia-cell-differentiation-protein-mcl-1-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//induced-myeloid-leukemia-cell-differentiation-protein-mcl-1-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//induced-myeloid-leukemia-cell-differentiation-protein-mcl-1-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments